Replies to post #176774 on Biotech Values

[DewDiligence]

BMY/GILD—FDA approves Evotaz FDC (Reyataz + Cobicstat):

http://finance.yahoo.com/news/u-food-drug-administration-approves-221900783.html

GILD’s Cobicstat (a constituent of Stribild and Complera) is an alternative to ritonavir for boosting BMY’s HIV protease inhibitor, Reyataz.

BMY will book sales of Evotaz; the companies haven’t disclosed how much GILD will be paid for the Cobicstat component.